Agouron Viracept monotherapy shows up to 97% reduction in HIV RNA at four months -- Phase II study.
AGOURON VIRACEPT MONOTHERAPY SHOWS UP TO 97% DECREASE IN HIV VIRAL LOAD after four months in a randomized Phase II dose-ranging study presented July 9 at the International Conference on AIDS in Vancouver by community-based researcher Marcus Conant, MD, Conant Medical Group, San Francisco. The study was conducted to optimize the dose and regimen for the ongoing Phase II/III trials with the protease inhibitor, which have enrolled 700 patients to date. Agouron has said it expects an NDA filing by the beginning of 1997 ("The Pink Sheet" June 3, T&G-13).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth